BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.87 -5.55%
EPS Growth %: +6.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: +6.7%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01. Revenue for the quarter came in at $163.35 million versus the consensus estimate of $149.82 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $608.4 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Waller: Recent Increases In Core Inflation Are Quite Broad
- Cosmos Health signs 5-year deal to sell diabetes drug in Greece
- Iran exported 57 million barrels of oil between Trump’s blockades
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
